📊 VERO Key Takeaways
Is Venus Concept Inc. (VERO) a Good Investment?
Venus Concept is in severe financial distress with no revenue growth, massive operating losses (-65% margin), and critical negative free cash flow (-$16.9M) against minimal cash reserves ($4.3M), indicating less than 2 months of runway. The company's equity base ($2.7M) has been decimated by cumulative losses, creating acute solvency risk and unsustainability of operations.
Why Buy Venus Concept Inc. Stock? VERO Key Strengths
- Gross margin of 62.6% indicates underlying product demand and pricing power in medical device market
- Medical instruments sector offers long-term growth potential if operational issues are resolved
- Current cash position of $4.3M provides short-term runway for operational adjustments
VERO Stock Risks: Venus Concept Inc. Investment Risks
- Critical liquidity crisis with current ratio of 0.90x and quick ratio of 0.59x below safe operational levels
- Severe cash burn of $16.9M in free cash flow against near-depleted cash reserves creates imminent solvency risk
- Deeply negative profitability with -$22.6M net income, -$28.1M operating loss, and -844% ROE indicates structural business model failure
- High leverage with 1.87x debt-to-equity ratio and negative interest coverage (-7.8x) limits financial flexibility
- Zero revenue growth with persistent operating losses suggests inability to achieve scale or cost management
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway (critical threshold: <3 months)
- Operating cash flow trajectory and path to cash flow breakeven
- Revenue growth rate and gross margin sustainability
- Debt covenant compliance status and refinancing risks
- Operating expense reduction progress and cost structure improvements
Venus Concept Inc. (VERO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
VERO Profit Margin, ROE & Profitability Analysis
VERO vs Healthcare Sector: How Venus Concept Inc. Compares
How Venus Concept Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Venus Concept Inc. Stock Overvalued? VERO Valuation Analysis 2026
Based on fundamental analysis, Venus Concept Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Venus Concept Inc. Balance Sheet: VERO Debt, Cash & Liquidity
VERO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Venus Concept Inc.'s revenue has declined by 28% over the 5-year period, indicating business contraction. The most recent EPS of $-68.47 indicates the company is currently unprofitable.
VERO Revenue Growth, EPS Growth & YoY Performance
VERO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $13.8M | -$9.3M | $-12.14 |
| Q2 2025 | $15.7M | -$9.8M | $-8.03 |
| Q1 2025 | $13.6M | -$9.8M | $-16.92 |
| Q3 2024 | $15.0M | -$9.3M | $-1.28 |
| Q2 2024 | $16.6M | -$7.4M | $-1.35 |
| Q1 2024 | $17.5M | -$9.7M | $-1.68 |
| Q3 2023 | $17.6M | -$7.4M | $-1.64 |
| Q2 2023 | $20.1M | -$7.4M | $-1.35 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Venus Concept Inc. Dividends, Buybacks & Capital Allocation
VERO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Venus Concept Inc. (CIK: 0001409269)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VERO
What is the AI rating for VERO?
Venus Concept Inc. (VERO) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VERO's key strengths?
Claude: Gross margin of 62.6% indicates underlying product demand and pricing power in medical device market. Medical instruments sector offers long-term growth potential if operational issues are resolved.
What are the risks of investing in VERO?
Claude: Critical liquidity crisis with current ratio of 0.90x and quick ratio of 0.59x below safe operational levels. Severe cash burn of $16.9M in free cash flow against near-depleted cash reserves creates imminent solvency risk.
What is VERO's revenue and growth?
Venus Concept Inc. reported revenue of $43.1M.
Does VERO pay dividends?
Venus Concept Inc. does not currently pay dividends.
Where can I find VERO SEC filings?
Official SEC filings for Venus Concept Inc. (CIK: 0001409269) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VERO's EPS?
Venus Concept Inc. has a diluted EPS of $-34.66.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VERO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Venus Concept Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VERO stock overvalued or undervalued?
Valuation metrics for VERO: ROE of -844.2% (sector avg: 15%), net margin of -52.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VERO stock in 2026?
Our dual AI analysis gives Venus Concept Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VERO's free cash flow?
Venus Concept Inc.'s operating cash flow is $-16.6M, with capital expenditures of $214.0K. FCF margin is -39.1%.
How does VERO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -52.3% (avg: 12%), ROE -844.2% (avg: 15%), current ratio 0.90 (avg: 2).
Is Venus Concept Inc. carrying too much debt?
VERO has a debt-to-equity ratio of 1.87x, which is above the Healthcare sector average of 0.6x. Combined with a current ratio below 1, this warrants careful monitoring of the balance sheet.